Avelumab and Merkel Cell Carcinoma: Examining the Evidence

From General Health Education to Specific Occupational Concerns

For decades, the general health and science information landscape has provided a foundational understanding of immune system function and its role in maintaining overall well-being. This legacy heritage has emphasized the delicate balance required for effective immune surveillance, particularly in the context of aging, environmental exposures, and therapeutic interventions. Within this broad framework, the scientific community has long recognized that certain pharmaceutical agents can modulate immune responses, sometimes with unintended consequences. The transition from general health education to specific occupational exposure concerns begins with the recognition that healthcare workers and pharmaceutical manufacturing personnel may encounter biologic agents in their professional environments. Avelumab, a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), represents a class of immunomodulatory therapies whose mechanisms of action involve altering immune checkpoint pathways. While the therapeutic benefits of such agents are well-documented in oncology, the potential implications of occupational exposure to these compounds warrant careful examination. The pivot from general health context to avelumab exposure and Merkel cell carcinoma risk thus emerges from a logical progression: understanding how immune modulation—whether therapeutic or inadvertent—may influence cancer susceptibility. This transition respects the legacy of immunology education while narrowing focus to a specific, occupationally relevant question about exposure and disease risk.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Epidemiology

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus; approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit in advanced MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% do not respond or develop immune-related adverse events due to diverse mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/).

Causation vs. Treatment: The Evidence on Avelumab and MCC Risk

The mechanistic pathway linking avelumab to Merkel cell carcinoma is not one of causation but of treatment: avelumab is used to treat MCC, not to cause it. The evidence indicates that avelumab is an approved therapy for metastatic MCC, and its use is associated with clinical responses in a subset of patients. For patients who are refractory to avelumab, treatment options are limited. Studies have investigated the activity of ipilimumab plus nivolumab in avelumab-refractory MCC. In a retrospective study at three German academic sites, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab and nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC, noting that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further confirmed that despite advances, about 50% of patients progress on immune checkpoint inhibitor therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Risk Context and Clinical Considerations

Regarding risk anchors, the adequacy of warnings about avelumab and MCC must be considered in the context of its approved indication. Avelumab is indicated for the treatment of metastatic MCC, and its prescribing information includes warnings about immune-related adverse events, which are common with checkpoint inhibitors. The evidence does not suggest that avelumab causes MCC; rather, it is a therapeutic agent for the disease. Causation-related considerations for affected patients therefore center on the natural history of MCC and the response to treatment, not on avelumab as a trigger. The timeline between exposure and documented harm is relevant to immune-related adverse events, which can occur during treatment, but not to the development of MCC itself. Patients who are refractory to avelumab may experience disease progression, and alternative therapies such as ipilimumab plus nivolumab have shown activity in this setting (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, the evidence supports that avelumab is an effective treatment for metastatic MCC, with approximately one-third of chemotherapy-refractory patients achieving objective responses. The risk of harm from avelumab is primarily related to immune-related adverse events, not to causation of MCC. For patients who do not respond or progress, combination immunotherapy with ipilimumab and nivolumab may offer benefit. The clinical presentation and diagnosis of MCC involve a rare, aggressive neuroendocrine cutaneous malignancy, and treatment with avelumab is a standard of care for metastatic disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is used to treat Merkel cell carcinoma, not cause it. It is an immune checkpoint inhibitor approved for metastatic MCC. The evidence shows it is a therapeutic agent, and its use is associated with clinical responses in some patients.

What is the evidence for avelumab in Merkel cell carcinoma?

The JAVELIN Merkel 200 trial showed objective responses in about one-third of chemotherapy-refractory metastatic MCC patients treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Additional studies confirm its efficacy and the potential benefit of combination immunotherapy in refractory cases (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.